**S2 Table. Factors associated with adverse events among patients with information about potentially modifiable details during EUS-FNA procedures (Adjusted)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **All regions (*n* = 359)†** | | **To the pancreas (*n* = 282)†** | |
|  | **Model 1‡ OR (95 % CI)** | **Model 2§ OR (95 % CI)** | **Model 1‡ OR (95 % CI)** | **Model 2§ OR (95 % CI)** |
| **ERCP on the same day** (ref: none) | 3.21 (1.58, 6.50)\* | 2.53 (1.21, 5.32)\* | 3.36 (1.57, 7.18)\* | 3.07 (1.42, 6.64)\* |
| **Number of punctures** | 1.24 (1.02, 1.51)\* | 1.19 (0.97, 1.46) |  |  |
| **Normal pancreas puncture, yes** | 1.94 (1.08, 3.46)\* | 1.89 (1.03, 3.47)\* | 1.97 (1.03, 3.77)\* | 1.76 (0.91, 3.41) |

†All adverse events among patients with EUS-FNA to any region (*n* = 60); pancreatitis among patients with EUS-FNA to the pancreas (*n* = 50)

EUS-FNA: Endoscopic ultrasound-guided fine needle aspiration; ERCP: Endoscopic retrograde cholangiopancreatography; ref: Reference

‡ Model 1 adjusted for age, sex, nature of lesion, and experience of endoscopists

§ Model 2 additionally adjusted for ERCP on the same day, number of punctures, and normal pancreas puncture

\**P* < 0.05